Visit https://www.peervoice.com/EFT860 to view the entire programme with slides. After completing “Evaluating the Evidence for Managing CKD: Highlights From World Congress of Nephrology 2021”, participants will be able to: Describe key safety and efficacy data on SGLT2 inhibition for the management of chronic kidney disease (CKD); Summarise what the latest data on SGLT2 inhibition add to the current treatment algorithm for CKD; Discuss the clinical implications of SGLT2 inhibition in the context of managing patients with CKD.